Categories
Resources
Your Recalls
Loading...
Get email alerts when new recalls match your interests.
Labeling: Label Mix-Up
Subpotent Drug
CGMP Deviations: the presence of a nitrosamine impurity, N-nitroso-cinacalcet, above the acceptable daily intake (ADI) limits.
CGMP Deviations: Presence of N-nitroso Cinacalcet impurity above FDA recommended interim limit
Marketed without an Approved NDA/ANDA: FDA analysis found the product to be tainted with undeclared diclofenac and acetaminophen.
Failed Impurities/Degradation Specifications.
Defective Container: Firm received complaints of broken tube at the seal.
Crystallization
Presence of Foreign Tablets/Capsules: A Carbamazepine Extended-Release 400 mg tablet was found in a 1000-count bottle of Atorvastatin Calcium Tablets, USP 40 mg.
Marketed without an approved NDA/ANDA: Product found to be tainted with undeclared dexamethasone and chlorpheniramine.
Lack of Assurance of Sterility: The impacted lots may contain a breach in the tube seal.
Incorrect/Undeclared Excipients: The inactive ingredients labeled on the product boxes and tubes are listed as "mineral oil , petrolatum ". The inactive ingredients in the actual product are polyethylene glycol 400 , polyethylene glycol 4000.
Failed Dissolution Specifications
Discoloration
Lack of Assurance of Sterility